Cargando…

A robust twelve-gene signature for prognosis prediction of hepatocellular carcinoma

BACKGROUND: The prognosis of hepatocellular carcinoma (HCC) patients remains poor. Identifying prognostic markers to stratify HCC patients might help to improve their outcomes. METHODS: Six gene expression profiles (GSE121248, GSE84402, GSE65372, GSE51401, GSE45267 and GSE14520) were obtained for di...

Descripción completa

Detalles Bibliográficos
Autores principales: Ouyang, Guoqing, Yi, Bin, Pan, Guangdong, Chen, Xiang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7268417/
https://www.ncbi.nlm.nih.gov/pubmed/32514252
http://dx.doi.org/10.1186/s12935-020-01294-9
_version_ 1783541613935460352
author Ouyang, Guoqing
Yi, Bin
Pan, Guangdong
Chen, Xiang
author_facet Ouyang, Guoqing
Yi, Bin
Pan, Guangdong
Chen, Xiang
author_sort Ouyang, Guoqing
collection PubMed
description BACKGROUND: The prognosis of hepatocellular carcinoma (HCC) patients remains poor. Identifying prognostic markers to stratify HCC patients might help to improve their outcomes. METHODS: Six gene expression profiles (GSE121248, GSE84402, GSE65372, GSE51401, GSE45267 and GSE14520) were obtained for differentially expressed genes (DEGs) analysis between HCC tissues and non-tumor tissues. To identify the prognostic genes and establish risk score model, univariable Cox regression survival analysis and Lasso-penalized Cox regression analysis were performed based on the integrated DEGs by robust rank aggregation method. Then Kaplan–Meier and time-dependent receiver operating characteristic (ROC) curves were generated to validate the prognostic performance of risk score in training datasets and validation datasets. Multivariable Cox regression analysis was used to identify independent prognostic factors in liver cancer. A prognostic nomogram was constructed based on The Cancer Genome Atlas (TCGA) dataset. Finally, the correlation between DNA methylation and prognosis-related genes was analyzed. RESULTS: A twelve-gene signature including SPP1, KIF20A, HMMR, TPX2, LAPTM4B, TTK, MAGEA6, ANX10, LECT2, CYP2C9, RDH16 and LCAT was identified, and risk score was calculated by corresponding coefficients. The risk score model showed a strong diagnosis performance to distinguish HCC from normal samples. The HCC patients were stratified into high-risk and low-risk group based on the cutoff value of risk score. The Kaplan–Meier survival curves revealed significantly favorable overall survival in groups with lower risk score (P < 0.0001). Time-dependent ROC analysis showed well prognostic performance of the twelve-gene signature, which was comparable or superior to AJCC stage at predicting 1-, 3-, and 5-year overall survival. In addition, the twelve-gene signature was independent with other clinical factors and performed better in predicting overall survival after combining with age and AJCC stage by nomogram. Moreover, most of the prognostic twelve genes were negatively correlated with DNA methylation in HCC tissues, which SPP1 and LCAT were identified as the DNA methylation-driven genes. CONCLUSIONS: We identified a twelve-gene signature as a robust marker with great potential for clinical application in risk stratification and overall survival prediction in HCC patients.
format Online
Article
Text
id pubmed-7268417
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-72684172020-06-07 A robust twelve-gene signature for prognosis prediction of hepatocellular carcinoma Ouyang, Guoqing Yi, Bin Pan, Guangdong Chen, Xiang Cancer Cell Int Primary Research BACKGROUND: The prognosis of hepatocellular carcinoma (HCC) patients remains poor. Identifying prognostic markers to stratify HCC patients might help to improve their outcomes. METHODS: Six gene expression profiles (GSE121248, GSE84402, GSE65372, GSE51401, GSE45267 and GSE14520) were obtained for differentially expressed genes (DEGs) analysis between HCC tissues and non-tumor tissues. To identify the prognostic genes and establish risk score model, univariable Cox regression survival analysis and Lasso-penalized Cox regression analysis were performed based on the integrated DEGs by robust rank aggregation method. Then Kaplan–Meier and time-dependent receiver operating characteristic (ROC) curves were generated to validate the prognostic performance of risk score in training datasets and validation datasets. Multivariable Cox regression analysis was used to identify independent prognostic factors in liver cancer. A prognostic nomogram was constructed based on The Cancer Genome Atlas (TCGA) dataset. Finally, the correlation between DNA methylation and prognosis-related genes was analyzed. RESULTS: A twelve-gene signature including SPP1, KIF20A, HMMR, TPX2, LAPTM4B, TTK, MAGEA6, ANX10, LECT2, CYP2C9, RDH16 and LCAT was identified, and risk score was calculated by corresponding coefficients. The risk score model showed a strong diagnosis performance to distinguish HCC from normal samples. The HCC patients were stratified into high-risk and low-risk group based on the cutoff value of risk score. The Kaplan–Meier survival curves revealed significantly favorable overall survival in groups with lower risk score (P < 0.0001). Time-dependent ROC analysis showed well prognostic performance of the twelve-gene signature, which was comparable or superior to AJCC stage at predicting 1-, 3-, and 5-year overall survival. In addition, the twelve-gene signature was independent with other clinical factors and performed better in predicting overall survival after combining with age and AJCC stage by nomogram. Moreover, most of the prognostic twelve genes were negatively correlated with DNA methylation in HCC tissues, which SPP1 and LCAT were identified as the DNA methylation-driven genes. CONCLUSIONS: We identified a twelve-gene signature as a robust marker with great potential for clinical application in risk stratification and overall survival prediction in HCC patients. BioMed Central 2020-06-03 /pmc/articles/PMC7268417/ /pubmed/32514252 http://dx.doi.org/10.1186/s12935-020-01294-9 Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Primary Research
Ouyang, Guoqing
Yi, Bin
Pan, Guangdong
Chen, Xiang
A robust twelve-gene signature for prognosis prediction of hepatocellular carcinoma
title A robust twelve-gene signature for prognosis prediction of hepatocellular carcinoma
title_full A robust twelve-gene signature for prognosis prediction of hepatocellular carcinoma
title_fullStr A robust twelve-gene signature for prognosis prediction of hepatocellular carcinoma
title_full_unstemmed A robust twelve-gene signature for prognosis prediction of hepatocellular carcinoma
title_short A robust twelve-gene signature for prognosis prediction of hepatocellular carcinoma
title_sort robust twelve-gene signature for prognosis prediction of hepatocellular carcinoma
topic Primary Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7268417/
https://www.ncbi.nlm.nih.gov/pubmed/32514252
http://dx.doi.org/10.1186/s12935-020-01294-9
work_keys_str_mv AT ouyangguoqing arobusttwelvegenesignatureforprognosispredictionofhepatocellularcarcinoma
AT yibin arobusttwelvegenesignatureforprognosispredictionofhepatocellularcarcinoma
AT panguangdong arobusttwelvegenesignatureforprognosispredictionofhepatocellularcarcinoma
AT chenxiang arobusttwelvegenesignatureforprognosispredictionofhepatocellularcarcinoma
AT ouyangguoqing robusttwelvegenesignatureforprognosispredictionofhepatocellularcarcinoma
AT yibin robusttwelvegenesignatureforprognosispredictionofhepatocellularcarcinoma
AT panguangdong robusttwelvegenesignatureforprognosispredictionofhepatocellularcarcinoma
AT chenxiang robusttwelvegenesignatureforprognosispredictionofhepatocellularcarcinoma